TD:NYSEToronto Dominion Bank (The) Analysis
Data as of 2026-06-17 - not real-time
$118.99
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
The stock is trading at $118.99, comfortably above its 20‑day SMA (≈$113.95) and 50‑day SMA (≈$108.87), with the 200‑day SMA still well below (≈$93.28), confirming a strong bullish trend. Momentum indicators reinforce this view: the RSI sits at 75, signaling an overbought condition, while the MACD line (≈2.78) sits above its signal line (≈2.50), producing a bullish histogram. Volume, however, is decreasing, and the price is hovering near the 52‑week high and the resistance level of $119.64, suggesting limited upside. Valuation metrics paint a less rosy picture: the current price exceeds the DCF‑derived fair value of roughly $100 and the median analyst target of $112.6, yielding an upside/downside estimate of –7.8%. The forward PE of 15.5 is modestly below the industry average of 17.2, yet the trailing PE of 19.5 indicates the stock trades at a premium.
Fundamentally, the bank delivers solid profitability with an operating margin of 35% and a ROE near 12%, and earnings are accelerating (forward EPS of $7.68 versus trailing $6.10). The balance sheet is robust, featuring a low beta of 0.71 and a 30‑day volatility of 17%, but the dividend is currently absent, raising questions about income‑focused investors. Overall, the technicals support continued momentum, but valuation pressure and the lack of dividend income suggest a cautious stance.
Fundamentally, the bank delivers solid profitability with an operating margin of 35% and a ROE near 12%, and earnings are accelerating (forward EPS of $7.68 versus trailing $6.10). The balance sheet is robust, featuring a low beta of 0.71 and a 30‑day volatility of 17%, but the dividend is currently absent, raising questions about income‑focused investors. Overall, the technicals support continued momentum, but valuation pressure and the lack of dividend income suggest a cautious stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near 52‑week high and resistance level
- RSI indicating overbought conditions
- Decreasing volume despite bullish MACD
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Strong operating margin and improving EPS
- Forward PE below industry average
- Valuation premium relative to DCF fair value
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Solid ROE and consistent earnings growth
- Diversified North American footprint reducing geographic concentration
- Potential reinstatement of dividend enhancing total return
Key Metrics & Analysis
Financial Health
Revenue Growth-31.50%
Profit Margin25.19%
P/E Ratio19.5
ROE11.91%
ROA0.72%
P/B Ratio2.2
Op. Cash Flow$5.5B
Industry P/E17.2
Technical Analysis
TrendBullish
RSI75.1
Support$108.01
Resistance$119.64
MA 20$113.95
MA 50$108.87
MA 200$93.28
MACDBullish
VolumeDecreasing
Fear & Greed Index91.77
Valuation
Fair Value$99.99
Target Price$109.73
Upside/Downside-7.78%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.71
Volatility17.03%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.